Kalif Eliyahu Sharon 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 6, 2025

Form 4

Period: 2025-03-04

EVP, Chief Financial Officer

Transactions

Exercise/Conversion
Ordinary Shares
2025-03-04+33,512→ 231,253 total
Exercise/Conversion
Ordinary Shares
2025-03-04+23,251→ 254,504 total
Exercise/Conversion
Ordinary Shares
2025-03-04+183,169→ 437,673 total
Exercise/Conversion
Restricted Share Units
2025-03-04−33,512→ 33,512 total
→ Ordinary Shares (33,512 underlying)
Exercise/Conversion
Restricted Share Units
2025-03-04−23,251→ 69,754 total
→ Ordinary Shares (23,251 underlying)
Exercise/Conversion
Restricted Share Units
2025-03-04−183,169→ 0 total
→ Ordinary Shares (183,169 underlying)

Footnotes (5)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
[F3]Restricted share units were granted on March 4, 2022, with 33,512 vested on each of March 4, 2023, March 4, 2024 and March 4, 2025, and 33,512 vesting on March 4, 2026.
[F4]Restricted share units were granted on March 4, 2024, with 23,251 vested on March 4, 2025, 23,251 vesting on each of March 4, 2026 and March 4, 2027, and 23,252 vesting on March 4, 2028.
[F5]Restricted share units were granted on January 28, 2025 pursuant to the satisfaction of performance criteria and vested on March 4, 2025.

Documents

1 file